High burden of human papillomavirus infection among men in Guangzhou, South China: Implications for HPV vaccination strategies

Hum Vaccin Immunother. 2024 Dec 31;20(1):2337161. doi: 10.1080/21645515.2024.2337161. Epub 2024 Apr 2.

Abstract

The epidemiological and clinical aspects of Human Papillomavirus (HPV) infection in women have been extensively studied. However, there is a lack of information regarding HPV characteristics in males. In this study, we conducted a retrospective and observational study of 3737 consecutive male individuals attending outpatient clinics of Guangdong Women and Children Hospital from 2012 to 2023 in Guangzhou, South China, to determine the age- and genotype-specific prevalence of HPV in men. The results showed the overall prevalence of HPV among men was 42.15% (1575/3737), with variations ranging from 29.55% to 81.31% across distinct diagnostic populations. Low-risk HPV6 (15.47%), HPV11 (8.94%), and high-risk HPV52 (5.51%) were the most common types. The annual HPV prevalence decreased significantly (Z = -3.882, p < .001), ranging from 31.44% to 52.90%. 28.77% (1075/3737) of men manifested infection with a singular HPV type, predominantly identified as a low-risk type. The age-specific distribution of HPV infections revealed distinctive peaks in the < 25 y age group (47.60%, 208/437) and the 40-44 y age group (44.51%, 154/346). Notably, the positive rate of Chlamydia trachomatis was significantly higher among HPV-positive individuals in comparison to HPV-negatives (16.14% vs. 11.25%, p < .05). Our findings reveal a substantial prevalence of HPV infection among outpatient men in Guangzhou, South China. It is recommended to consider the inclusion of HPV vaccination for adolescent males in national immunization schedules, once an adequate supply of vaccines is accessible.

Keywords: Chlamydia trachomatis; Human papillomavirus; South China; epidemiology; men.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • China / epidemiology
  • Genotype
  • Humans
  • Male
  • Papillomaviridae / genetics
  • Papillomavirus Infections* / epidemiology
  • Papillomavirus Infections* / prevention & control
  • Prevalence
  • Retrospective Studies
  • Risk
  • Uterine Cervical Neoplasms* / prevention & control
  • Vaccination
  • Young Adult

Grants and funding

This work was supported by the Guangdong Medical Science and Technology Research Fund [grant number A2023410] and the Guangzhou Science and Technology Planning Project [grant number A202103000047].